Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies ...

A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...

Please provide your email address to receive an email when new articles are posted on . Patients with constipation-predominant irritable bowel syndrome treated with a ...

August 30, 2012 — The US Food and Drug Administration (FDA) approved the drug linaclotide (Linzess, Ironwood Pharmaceuticals) today for the treatment of chronic idiopathic constipation and irritable ...

The FDA approved linaclotide (Linzess) capsules to treat irritable bowel syndrome with constipation (IBS-C) in children age 7 years and older, the agency announced Wednesday. The decision makes the ...

There was no significant difference between the two therapies in odds ratios for efficacy, diarrhea, or diarrhea-related study withdrawals. Researchers aimed to evaluate the safety and efficacy of GCC ...

(HealthDay News) – Over 26 weeks of treatment, the peptide guanylate cyclase-C agonist linaclotide significantly improves abdominal pain and bowel symptoms in patients with irritable bowel syndrome ...

Linaclotide is marketed by Allergan for the treatment of adults with moderate to severe IBS-C in Europe under the brand name CONSTELLA®. Ironwood is partnered with AstraZeneca for development and ...

August 11, 2011 — The investigative drug linaclotide has been shown in 2 phase 3 placebo-controlled trials to safely and effectively reduce bowel and abdominal symptoms associated with chronic ...

A study, published in The American Journal of Gastroenterology, examined the efficacy and safety of linaclotide for patients with chronic idiopathic constipation. Philip Schoenfeld, MD, of ...

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving ...

Linzess (linaclotide), a medication for irritable bowel syndrome (IBS) with constipation or chronic idiopathic constipation is now available in American pharmacies, Ironwood Pharmaceuticals Inc. and ...